US Patent 9783823 Cytomegalovirus vectors enabling control of T cell targeting
Patent 9783823 was granted and assigned to Oregon Health & Science University on October, 2017 by the United States Patent and Trademark Office.
All edits
CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
US Patent 09783823 Cytomegalovirus vectors enabling control of T cell targeting US Patent 9783823 Cytomegalovirus vectors enabling control of T cell targeting
US Patent 09783823 Cytomegalovirus vectors enabling control of T cell targeting
Find more entities like US Patent 9783823 Cytomegalovirus vectors enabling control of T cell targeting
